Literature DB >> 18006891

Preclinical evidence that sildenafil and vardenafil activate chloride transport in cystic fibrosis.

Bob Lubamba1, Hugues Lecourt, Jean Lebacq, Patrick Lebecque, Hugo De Jonge, Pierre Wallemacq, Teresinha Leal.   

Abstract

RATIONALE: Sildenafil has been implicated in the activation of cystic fibrosis transmembrane conductance regulator (CFTR) protein. The effect was observed in vitro and in the presence of doses roughly 300 times larger than those commonly used for treating erectile dysfunction.
OBJECTIVES: To evaluate in vivo the therapeutic efficacy of clinical doses of sildenafil and vardenafil, two clinically approved phosphodiesterase 5 inhibitors, for activating ion transport in cystic fibrosis.
METHODS: We used transepithelial potential difference in vivo across the nasal mucosa as a measure of sodium and chloride transport. The effect of a single intraperitoneal injection of sildenafil (0.7 mg/kg) or vardenafil (0.14 mg/kg) was investigated in F508del, cftr knockout and normal homozygous mice.
MEASUREMENTS AND MAIN RESULTS: In F508del mice, but not in cftr knockout mice, the chloride conductance, evaluated by perfusing the nasal mucosa with a chloride-free solution in the presence of amiloride and with forskolin, was corrected 1 hour after sildenafil administration. A more prolonged effect, persisting for at least 24 hours, was observed with vardenafil. The forskolin response was increased after sildenafil and vardenafil in both normal and F508del mutant animals. In F508del mice, the chloride conductance in the presence of 200 microM 4-4'-diisothiocyanostilbene-2,2'-disulphonic acid, an inhibitor of alternative chloride channels, was much higher after sildenafil injection than after placebo treatment. No effect on the sodium conductance was detected in any group of animals.
CONCLUSIONS: Our results provide preclinical evidence that both drugs stimulate chloride transport activity of F508del-CFTR protein.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18006891     DOI: 10.1164/rccm.200703-344OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  23 in total

Review 1.  Chloride channels as drug targets.

Authors:  Alan S Verkman; Luis J V Galietta
Journal:  Nat Rev Drug Discov       Date:  2008-01-19       Impact factor: 84.694

Review 2.  Protein processing and inflammatory signaling in Cystic Fibrosis: challenges and therapeutic strategies.

Authors:  C N Belcher; N Vij
Journal:  Curr Mol Med       Date:  2010-02       Impact factor: 2.222

Review 3.  Breakthrough therapies: Cystic fibrosis (CF) potentiators and correctors.

Authors:  George M Solomon; Susan G Marshall; Bonnie W Ramsey; Steven M Rowe
Journal:  Pediatr Pulmonol       Date:  2015-06-19

4.  Pharmacokinetics and tolerability of oral sildenafil in adults with cystic fibrosis lung disease.

Authors:  J L Taylor-Cousar; C Wiley; L A Felton; C St Clair; M Jones; D Curran-Everett; K Poch; D P Nichols; G M Solomon; M T Saavedra; F J Accurso; J A Nick
Journal:  J Cyst Fibros       Date:  2014-11-13       Impact factor: 5.482

Review 5.  Cystic fibrosis transmembrane conductance regulator protein repair as a therapeutic strategy in cystic fibrosis.

Authors:  Peter A Sloane; Steven M Rowe
Journal:  Curr Opin Pulm Med       Date:  2010-11       Impact factor: 3.155

Review 6.  Cystic fibrosis transmembrane conductance regulator modulators for personalized drug treatment of cystic fibrosis: progress to date.

Authors:  Frédéric Becq
Journal:  Drugs       Date:  2010-02-12       Impact factor: 9.546

7.  Nasal Potential Difference to Quantify Trans-epithelial Ion Transport in Mice.

Authors:  Mathilde Beka; Teresinha Leal
Journal:  J Vis Exp       Date:  2018-07-04       Impact factor: 1.355

Review 8.  Cystic fibrosis transmembrane regulator correctors and potentiators.

Authors:  Steven M Rowe; Alan S Verkman
Journal:  Cold Spring Harb Perspect Med       Date:  2013-07-01       Impact factor: 6.915

9.  Optical Nanosensors for in vivo Physiological Chloride Detection for Monitoring Cystic Fibrosis Treatment.

Authors:  Wenjun Di; Heather A Clark
Journal:  Anal Methods       Date:  2020-02-26       Impact factor: 2.896

Review 10.  On the Corner of Models and Cure: Gene Editing in Cystic Fibrosis.

Authors:  Marjolein Ensinck; Angélique Mottais; Claire Detry; Teresinha Leal; Marianne S Carlon
Journal:  Front Pharmacol       Date:  2021-04-27       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.